Intellia Therapeutics (NTLA) experienced a surprising surge of 5.04% in Tuesday's trading session, defying a series of analyst downgrades. The stock's resilience in the face of seemingly negative news has caught the attention of market observers.

Several prominent financial institutions revised their outlook on Intellia Therapeutics. Evercore ISI downgraded the stock from Outperform to In-Line, adjusting their price target to $8 from $17. Similarly, Jonestrading cut their rating to Hold, while Wedbush maintained their Hold rating with a price target of $7.00. Despite these cautious stances from analysts, investors appeared to have a different perspective, driving the stock higher.

The stark contrast between analyst sentiment and market behavior suggests that other factors may be influencing Intellia Therapeutics' stock performance. It's possible that investors are focusing on potential catalysts not fully reflected in analyst reports, or that the market is reacting to information not captured in the recent downgrades. As the situation develops, market participants will be keen to understand the underlying drivers of this unexpected stock movement.